SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001628280-23-032817
Filing Date
2023-09-22
Accepted
2023-09-22 08:03:36
Documents
16
Period of Report
2023-09-22
Items
Item 3.03: Material Modifications to Rights of Security Holders
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K nltx-20230922.htm   iXBRL 8-K 30283
2 EX-3.1 a31-certificateofamendment.htm EX-3.1 11314
3 EX-99.1 a991-pressreleaserss_final.htm EX-99.1 10188
8 image_0a.jpg GRAPHIC 12981
  Complete submission text file 0001628280-23-032817.txt   235442

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT nltx-20230922.xsd EX-101.SCH 2146
5 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT nltx-20230922_def.xml EX-101.DEF 14907
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT nltx-20230922_lab.xml EX-101.LAB 28853
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT nltx-20230922_pre.xml EX-101.PRE 15561
10 EXTRACTED XBRL INSTANCE DOCUMENT nltx-20230922_htm.xml XML 2827
Mailing Address SUITE 360 - 1616 EASTLAKE AVE EAST SEATTLE WA 98102
Business Address SUITE 360 - 1616 EASTLAKE AVE EAST SEATTLE WA 98102 206-732-2133
Neoleukin Therapeutics, Inc. (Filer) CIK: 0001404644 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36327 | Film No.: 231270264
SIC: 2834 Pharmaceutical Preparations